A nanoparticle designed to treat soft tissue sarcoma has passed its first hurdle with the successful conclusion of a Phase 1 study in patients with the disease. The developer, Nanobiotix SA, plans to position the product alongside radiotherapy as a treatment for patients with locally advanced sarcoma for whom few treatment options exist.
